OS
Extended Data Fig. 3 · Panel A
Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Caicun Zhou, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Iris Yan, Li Qian, Miao Xu, Xiayu Huang, Chun Sun, Jun Cai, Qiong Wu, Marcus Ballinger, Monika Kaul, Minu K Srivastava
Nat Med 31(7) 2375-2384
After the global approval of atezolizumab plus bevacizumab and chemotherapy as first-line metastatic nonsquamous non-small-cell lung cancer (nsqNSCLC) treatment, the IMpower151 ( NCT04194203 ) trial was conducted in China to address regional differences. Chemotherapy-naive patients with metastatic nsqNSCLC (N = 305) were randomized 1:1 to receive either atezolizumab, bevacizumab, carboplatin and paclitaxel or pemetrexed (ABCPem/Pac; n = 152) or placebo plus bevacizumab, carboplatin and pemetrexed or paclitaxel (BCPem/Pac; n = 153). The primary endpoint was investigator-assessed progression-free survival (INV-PFS); secondary endpoints included subgroup analyses of INV-PFS, independent review facility-assessed PFS, overall survival, and investigator-assessed objective response rate and duration of response per RECIST v.1.1. Most patients (97%) received pemetrexed, and 53% had EGFR+ tumors. Median INV-PFS for ABCPem/Pac versus BCPem/Pac was 9.5 versus 7.1 months (stratified hazard ratio: 0.84; 95% confidence interval: 0.65, 1.09; P = 0.184). INV-PFS across subgroups and independent review facility-assessed PFS were consistent with INV-PFS in the intention-to-treat population. Median overall survival was 20.7 versus 18.7 months in the ABCPem/Pac versus BCPem/Pac arms, respectively (stratified hazard ratio: 0.93; 95% confidence interval: 0.67, 1.28). Confirmed objective response rate with ABCPem/Pac versus BCPem/Pac was 48% versus 50%, respectively; median duration of response was 11.3 versus 8.3 months. Adverse events of special interest for atezolizumab were observed in 68% (grades 3 and 4: 11%) and 71% (grades 3 and 4: 7%) of patients receiving ABCPem/Pac and BCPem/Pac, respectively. The most common adverse events of special interest for atezolizumab in the ABCPem/Pac and BCPem/Pac arms were hepatitis (driven by laboratory abnormalities; mostly low grade), hypothyroidism and rash. Overall, IMpower151 did not meet its primary endpoint (INV-PFS) in metastatic nsqNSCLC. ABCPem/Pac was generally well tolerated, with no new safety signals. Trial registration number: ClinicalTrials.gov, NCT02366143.
1 个 Figure · 2 个 KM 面板
OS by EGFR mutation status. Kaplan-Meier curves in patients with ( a ) EGFR mutation and ( b ) EGFR WT. EGFR mutation status was based on the presence of EGFR genomic alterations or ALK rearrangements. Sensitizing EGFR mutations include exon 19 del, L858R, S768I, L861Q, and G719X. ( c ) OS in key patient subgroups of the EGFR mutation group. Data markers in (c) represent HRs, with error bars indicating 95% CIs. a Unstratified HR is reported. b Includes patients with sensitizing EGFR mutations S768I, L861Q and G719X (n = 7). c Two patients in the ABCPem/Pac arm had both sensitizing EGFR mutations exon19 del and L858R. d One patient was wrongly randomized as EGFR WT in the interactive voice- or web-based response system and had received no prior TKI treatment. e Prior lines were counted only when the reason for stopping was disease progression. f One patient with EGFR mutation received EGFR TKI but the reason for stopping was not disease progression. 1G, first generation; 2G, second generation; 3G, third generation; ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; ALK , anaplastic large-cell lymphoma kinase; BCPem/Pac, placebo plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; CI, confidence interval; EGFR , epidermal growth factor receptor; HR, hazard ratio; NE, not estimable; TKI, tyrosine kinase inhibitor; WT, wild type.
这些图片未产生 KM 曲线结果,不在主页面重复展示。